<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245465</url>
  </required_header>
  <id_info>
    <org_study_id>H-B-2008-FSP-20</org_study_id>
    <nct_id>NCT01245465</nct_id>
  </id_info>
  <brief_title>Profermin® in Active Ulcerative Colitis</brief_title>
  <acronym>CUPE-1</acronym>
  <official_title>Safety and Efficacy of Profermin® to Induce Remission in Patients With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordisk Rebalance A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordisk Rebalance A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators aim was to investigate the safety and possible efficacy of
      Profermin® in patients with ulcerative colitis. The investigators also aimed at assessing the
      usefulness of a new online daily symptom registration system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Our primary endpoint was to estimate the proportion of patients with a reduction in SCCAI ≥50%.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Daily report of SCCAI symptoms on the Internet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Our secondary endpoint was to estimate the proportion of patients in remission defined as SCCAI lower than or equal to 2.5</measure>
    <time_frame>24 weeks</time_frame>
    <description>Daily report of SCCAI symptoms on the Internet</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Profermin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral intake of a food for special medical purposes (Profermin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Profermin</intervention_name>
    <description>Medical Food (food for special medical purposes)</description>
    <arm_group_label>Profermin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients were eligible if they were between 18 and 50 years of age and
        had an established diagnosis of UC based on clinical, endoscopic and histological features.
        Active disease was assessed by Simple Clinical Colitis Activity Index (SCCAI) (Table 1)
        score above 4 and below 12.

        Exclusion Criteria:

        Patients who initiated treatment with azathioprine, 6-mercaptopurine, ciclosporin or
        methotrexate within 8 weeks prior to inclusion or TNF-α inhibitors within 12 weeks before
        inclusion or had changes in UC treatment within 2 weeks before inclusion were ineligible
        for the study. Concomitant coeliac disease or lactose intolerance were also exclusion
        criteria. In addition any malignant or premalignant condition or recent gastroenteritis
        rendered patients ineligible-
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Israelsen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nordisk Rebalance A/S</affiliation>
  </overall_official>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2010</study_first_posted>
  <last_update_submitted>November 22, 2010</last_update_submitted>
  <last_update_submitted_qc>November 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hans Israelsen</name_title>
    <organization>Noreba</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

